We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Technology for 3D Whole Genome Mapping Research

By LabMedica International staff writers
Posted on 03 Dec 2009
Scientists in Singapore report a technologic development in the study of gene expression and regulation in the genome's three-dimensional (3D) folding and looping state through the development of an innovative technology. More...


The technology is called ChIA-PET (Chromatin Interaction Analysis using Paired End Tag sequencing). Chromatin is a complex combination of DNA and proteins that comprise chromosomes.

The study was published online November 5, 2009, in the journal Nature, by scientists from the Genome Institute of Singapore (GIS) "Many studies have found that regions of the genome which are not near genes are very important in controlling disease,” said Melissa Fullwood, Ph.D., first author of the research article and member of a team of GIS scientists led by Yijun Ruan, Ph.D., senior group leader and associate director of genomic technologies, and senior research scientist Edwin Cheung, Ph.D.

"In thinking about how this can happen, many scientists hypothesized that chromatin interactions--three-dimensional loops in DNA--might be what allow these regions to remotely talk to genes,” Dr. Fullwood added. "The subsequent discovery of chromatin interactions between specific genes and specific enhancer sites generated a lot of interest to find chromatin interactions throughout the entire genome. Our study is one of the first to be able to address this ‘Holy Grail' of genomics.”

Ever since the human genome was found to be organized in a three-dimensional (3D) way rather than in a two-dimensional linear manner, scientists have been challenged to find an effective method to study the regulation of gene activity that took into account the complexities of its 3D structure.

Utilizing ChIA-PET technology, the GIS scientists have successfully met the challenge and validated the presence of genome-wide long-range chromatin interactions. Using the estrogen receptor-a (ERa) as a model, the GIS scientists investigated how the human genome was organized in response to estrogen signaling to control the expression of genes in breast cancer cells. They discovered that extensive ERa-bound long-range chromatin interactions in the human genome were involved as a primary mechanism for regulating estrogen-mediated gene expression.

"Our institute had been working to develop this technology to answer a fundamental question in cancer. These results show us that higher order DNA interactions on a genome scale can explain some of the contradictions in older studies. This work will pave the way for the development of highly specific anti-hormone treatments in breast cancer,” said Edison Liu, M.D., executive director of GIS, one of the research institutes sponsored by Singapore's Agency for Science, Technology and Research (A*STAR).

"The study represents a true scientific tour de force. It shows a massive genome-wide scale the interactions between a specific set of enhancers and the genes they regulate. The approach and results shown here will certainly be well received by the large community studying gene regulation,” said Edward Rubin, M.D., Ph.D., director of the genomics Division at the Lawrence Berkeley National Laboratory, University of California, (USA).

The ChIA-PET methodology and the ERa-bound human chromatin interaction map represent the starting point of an entirely new field for scientists to study how the human genome is folded in order to communicate the codes in regulating gene expression. Vital for unraveling the mechanisms of genome control during cell differentiation, ChIA-PET and the chromatin interaction map may lead to a better understanding and control of diseases. This technique was based on a revolutionary gene sequencing method known as paired-end ditag (PET) sequencing, which was developed in 2005 by GIS scientists, led by senior group leaders Yijun Ruan, Ph.D., and Chia-Lin Wei, Ph.D.

This work has been recognized and funded by a grant from the U.S. National Institutes of Health's (NIH; Bethesda, MD, USA) public research consortium known as ENCODE (Encyclopedia of DNA Elements).

Related Links:

Genome Institute of Singapore




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.